Cargando…

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging

BACKGROUND: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. RESULTS: Erlotinib distribution in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimura, Meiko, Hayashi, Mitsuhiro, Mizutani, Yu, Takenaka, Kei, Imamura, Yoshinori, Chayahara, Naoko, Toyoda, Masanori, Kiyota, Naomi, Mukohara, Toru, Aikawa, Hiroaki, Fujiwara, Yasuhiro, Hamada, Akinobu, Minami, Hironobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915091/ https://www.ncbi.nlm.nih.gov/pubmed/29719624 http://dx.doi.org/10.18632/oncotarget.24928

Ejemplares similares

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
por: Nishimura, Meiko, et al.
Publicado: (2016)

Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Tsubata, Yukari, et al.
Publicado: (2017)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
por: Funakoshi, Yohei, et al.
Publicado: (2016)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study
por: Takenaka, Kei, et al.
Publicado: (2015)

Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
por: Sai, Satoshi, et al.
Publicado: (2021)

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells
por: Nishidate, Masanobu, et al.
Publicado: (2017)

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
por: Kast, R. E.
Publicado: (2015)

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
por: Chayahara, Naoko, et al.
Publicado: (2019)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function
por: Goto, Keiko, et al.
Publicado: (2019)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash
por: Lee, Won Kil, et al.
Publicado: (2023)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
por: Kainis, Ilias, et al.
Publicado: (2018)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Toxicité cutanée à l'erlotinib
por: Bourra, Hayat, et al.
Publicado: (2013)

Stability and Formulation of Erlotinib in Skin Creams
por: Nguyen, David, et al.
Publicado: (2022)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

A Case of Cicatricial Alopecia Associated with Erlotinib
por: Yang, Bo Hee, et al.
Publicado: (2011)

Erlotinib hydrochloride: an anticancer agent
por: Selvanayagam, S., et al.
Publicado: (2008)

Acute Fatal Liver Toxicity under Erlotinib
por: Schacher-Kaufmann, Sabina, et al.
Publicado: (2010)

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma
por: ZHANG, HUAN-HUAN, et al.
Publicado: (2013)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Matrix‐assisted laser desorption ionization ‐ mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non‐small‐cell lung cancer mouse xenograft model
por: Kim, Tae Young, et al.
Publicado: (2021)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7s7d6enghr95g3b3vemgc3oamb